Thank you.
I lost some time.
So what is it about this flexibility that would not be found in the guidelines of the Patented Medicine Prices Review Board, the PMPRB? Are you telling us indirectly that you did not control the price of drugs so that they are not excessive, as part of this relaxation? If not, how can the PMPRB reassure a patient with a rare disease? Is such a patient less important than a patient with COVID‑19?
Some say that your reform will result in fewer clinical trials.